Tectonic Therapeutic, Inc. (TECX) P/E Ratio History
Historical price-to-earnings valuation from 2023 to 2024
Loading P/E history...
TECX Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 7, 2026, Tectonic Therapeutic, Inc. (TECX) trades at a price-to-earnings ratio of -6.6x, with a stock price of $26.87 and trailing twelve-month earnings per share of $-4.45.
The current P/E is 357% below its 5-year average of 2.6x. Over the past five years, TECX's P/E has ranged from a low of 1.1x to a high of 4.7x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, TECX trades at a 130% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, TECX trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our TECX DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
TECX P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $6B | 24.8 | - | -34% | |
| $8B | 25.5 | 1.11 | -25% | |
| $4B | 9.9 | - | +68% | |
| $2B | 6.9Lowest | 0.67Best | +817%Best |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
TECX Historical P/E Data (2023–2024)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2024 Q1 | Sun Mar 31 2024 00:00:00 GM | $15.36 | $13.43 | 1.1x | -56% |
| FY2023 Q4 | Sun Dec 31 2023 00:00:00 GM | $16.32 | $8.45 | 1.9x | -25% |
| FY2023 Q3 | Sat Sep 30 2023 00:00:00 GM | $18.48 | $3.95 | 4.7x | +81% |
Average P/E for displayed period: 2.6x
See TECX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs TECX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare TECX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonTECX — Frequently Asked Questions
Quick answers to the most common questions about buying TECX stock.
Is TECX stock overvalued or undervalued?
TECX trades at -6.6x P/E, below its 5-year average of 2.6x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does TECX's valuation compare to peers?
Tectonic Therapeutic, Inc. P/E of -6.6x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is TECX's PEG ratio?
TECX PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2023-2024.